Prognostic value of visual IMPeTUs criteria and metabolic tumor burden at baseline [18F]FDG PET/CT in patients with newly diagnosed multiple myeloma

被引:1
|
作者
Marchiori, Silvano [1 ]
Cousin, Francois [1 ]
Papadopoulos, Iraklis [2 ]
Bernard, Claire [1 ]
Thys, Marie [3 ]
De Prijck, Bernard [4 ]
Pirotte, Michelle [4 ]
Donneau, Anne-Francoise [2 ]
Hustinx, Roland [1 ,5 ]
Caers, Jo [4 ,6 ]
Withofs, Nadia [1 ,5 ]
机构
[1] CHU Liege, Dept Med Phys, Div Nucl Med & Oncol Imaging, Liege, Belgium
[2] Univ Liege, Biostat & Res Methods Ctr B STAT, Liege, Belgium
[3] CHU Liege, Med Econ Informat Dept Data Anal, Liege, Belgium
[4] CHU Liege, Dept Hematol, Liege, Belgium
[5] Univ Liege, GIGA CRC Vivo Imaging, Liege, Belgium
[6] Univ Liege, Lab Hematol, GIGA I3, Liege, Belgium
来源
EJNMMI RESEARCH | 2024年 / 14卷 / 01期
关键词
Myeloma; PET; FDG; Imaging; MTV; TOMOGRAPHY-COMPUTED TOMOGRAPHY; F-18-FDG PET/CT; FDG PET/CT; FOLLOW-UP; BORTEZOMIB; PREDICTION; PHASE-3;
D O I
10.1186/s13550-024-01113-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background 2-[F-18]fluoro-2-deoxy-D-glucose ([F-18]FDG) positron emission tomography combined with low-dose computed tomography (PET/CT) can be used at diagnosis to identify myeloma-defining events and also provides prognostic factors. The aim of this study was to assess the prognostic significance of baseline [F-18]FDG PET/CT visual IMPeTUs (Italian myeloma criteria for PET Use)-based parameters and/or total metabolic tumor volume (TMTV) in a single-center population of patients with newly diagnosed multiple myeloma (NDMM) eligible for transplantation. Methods Patients with MM who underwent a baseline [F-18]FDG PET/CT were retrospectively selected from a large internal database of the University Hospital of Liege (Liege, Belgium). Initially, all PET/CT images were visually analyzed using IMPeTUs criteria, followed by delineation of TMTV using a semi-automatic lesion delineation workflow, including [F-18]FDG-positive MM focal lesions (FL) with an absolute SUV threshold set at 4.0. In a first step, to ensure PET/CT scans accurate reporting, the agreement between two nuclear medicine physicians with distinct experience was assessed. In the second step, univariable and multivariable analyses were conducted to determine the prognostic significance of [F-18]FDG PET/CT parameters on progression free survival (PFS) and overall survival (OS), respectively. Results A total of 40 patients with NDMM were included in the study. The observers agreement in the analysis [18F]FDG PET/CT images was substantial for the presence of spine FL, extra spine FL, at least one fracture and paramedullary disease (Cohen's kappa 0.79, 0.87, 0.75 and 0.64, respectively). For the presence of skull FL and extramedullary disease the agreement was moderate (Cohen's kappa 0.56 and 0.53, respectively). Among [F-18]FDG PET/CT parameters, a high number of delineated volumes of interest (VOI) using the SUV4.0 threshold was the only independent prognostic factor associated with PFS [HR (95% CI): 1.03 (1.004-1.05), P = 0.019] while a high number of FL (n > 10; F group 4) was the only independent prognostic factor associated with OS [HR (95% CI): 19.10 (1.90-191.95), P = 0.01]. Conclusion Our work confirms the reproducibility IMPeTUs criteria. Furthermore, it demonstrates that a high number of FL (n > 10; IMPeTUs F group 4), reflecting a high [F-18]FDG-avid tumor burden, is an independent prognostic factor for OS. The prognostic value of the TMTV delineated using a SUV4.0 threshold was not significant. Nevertheless, the count of delineated [F-18]FDG-avid lesions VOI using a SUV4.0 threshold was an independent prognostic factor for PFS.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Interstitial Lung Involvement of Multiple Myeloma on 18F FDG PET/CT
    Keskin, M.
    Temelli, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S670 - S671
  • [42] Sarcopenia and metabolic parameters of [18F]-FDG PET/CT in patients with multiple myeloma. Preliminary results.
    Palomar-Munoz, A.
    Hermosa-Garcia, S.
    Sanchez-Rodriguez, I.
    Benavente, Y.
    Jorge-Novoa, J. A.
    Carrero-Vasquez, V.
    Hervas-Sanz, B.
    Garamundi-Grimalt, E.
    Bustamante-Ramirez, G.
    Cabezudo-Perez, E.
    Cortes-Romera, M.
    Casabonne, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S572 - S573
  • [43] Prognostic value of baseline and interim [18F]FDG PET metabolic parameters in pediatric Hodgkin's lymphoma
    Yadgarov, Mikhail Ya.
    Dunaykin, M. M.
    Shestopalov, G. I.
    Kailash, C.
    Kireeva, E. D.
    Myakova, N. V.
    Likar, Yu. N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (07) : 1955 - 1964
  • [44] Prognostic Value of Baseline 18F-Fluorodeoxyglucose PET/CT in Patients with Multiple Myeloma: A Multicenter Cohort Study
    Moon, Seung Hwan
    Choi, Woo Hee
    Yoo, Ie Ryung
    Lee, Soo Jin
    Paeng, Jin Chul
    Jeong, Shin Young
    Lee, Sang-Woo
    Kim, Kihyun
    Choi, Joon Young
    KOREAN JOURNAL OF RADIOLOGY, 2018, 19 (03) : 481 - 488
  • [45] Clinical value of 18F-FDG PET/CT in patients with newly diagnosed acute leukemia
    Fang, Jiamin
    Chen, Jie
    Li, Xinqi
    Li, Pengpeng
    Liu, Xiaoyan
    He, Yong
    Zhou, Fuling
    CELLULAR ONCOLOGY, 2024, 47 (06) : 2135 - 2145
  • [46] The value of 18F-FDG PET/CT in the diagnosis of multiple myeloma
    Niu, Xiaobo
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S486 - S487
  • [47] Prognostic value of metabolic indices in baseline 18F-FDG PET/CT for pediatric Burkitt lymphoma
    Roshdy, E.
    Hamoda, A.
    Salah, A.
    NasrEldin, E.
    Zaher, A.
    Romeih, M.
    Mingels, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S234 - S234
  • [48] Metabolic tumor volume assessed by 18F-FDG-PET/CT as a predictor of outcome in patients with multiple myeloma
    Fonti, R.
    Larobina, M.
    De Luca, S.
    Fabbricini, R.
    Catalano, L.
    Rotoli, B.
    Pace, L.
    Del Vecchio, S.
    Salvatore, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S354 - S354
  • [49] The prognostic value of [18F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria
    Christos Sachpekidis
    Vivienn Weru
    Annette Kopp-Schneider
    Jessica C. Hassel
    Antonia Dimitrakopoulou-Strauss
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 2699 - 2714
  • [50] The prognostic value of [18F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria
    Sachpekidis, Christos
    Weru, Vivienn
    Kopp-Schneider, Annette
    Hassel, Jessica C.
    Dimitrakopoulou-Strauss, Antonia
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (09) : 2699 - 2714